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CObjective: To explore the “healthy user” and “healthy adherer” ef-
fects—hypothetical sources of bias thought to arise when patients who
initiate and adhere to preventive therapies are more likely to engage in
healthy behaviors than are other subjects. Methods: The authors ex-
mined the association between statin initiation and adherence, and
he subsequent use of preventive health services and incidence of clin-
cal outcomes unlikely to be associated with the need for, or use of, a
tatin among older enrollees in two state-sponsored drug benefit
rograms. Results: After adjustment for demographic and clinical co-
ariates, patients who initiated statin use were more likely to receive
ecommended preventive services than noninitiators matched on age,
ex, and state (hazard ratio [HR]: 1.10, 1.06–1.14 for males, HR: 1.09,
.07–1.11 for females) and appeared to have a lower risk of a range of O
en’s
al So
doi:10.1016/j.jval.2010.10.033dverse outcomes (HR: 0.87, 0.85–0.89) thought to be unrelated to statin
se. Adherence to a statin regimen was also associated with increased
ates of preventive service use and a decreased rate of adverse clinical
utcomes (HR: 0.93, 0.88–0.99). Conclusions: These results suggest
hat patients initiating and adhering to chronic preventive drug thera-
ies are more likely to engage in other health-promoting behaviors.
ailure to account for this relationship may introduce bias in any epi-
emiologic study evaluating the effect of a preventive therapy on clin-
cal outcomes.
eywords: bias, confounding factors, epidemiologic methods, health
ehavior, pharmacoepidemiology.
opyright © 2011, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
The healthy user and healthy adherer effects have gained increas-
ing attention as potential sources of bias in observational studies.
Widely cited as a likely contributor to the divergence between
observational and randomized controlled trial (RCT) evidence con-
cerning the relationship between estrogen replacement therapy
and cardiovascular mortality [1–4], the healthy user effect has also
been raised as an explanation for the finding that elderly subjects
receiving flu shots have lower mortality rates in the pre-flu season
[5]. A close relative of the healthy user effect, the healthy adherer
effect, has been implicated in the observation that patients adher-
ent to placebo in RCTs have lower mortality rates than patients
less adherent to placebo, which was documented in a recent meta-
analysis of 21 RCTs [6]. These effects should be of interest and
concern both to researchers conducting observational studies and
to readers of such studies.
The healthy user effect, also known as “healthy user bias,” arises
when healthier patients are more likely to initiate a preventive ther-
apy, either through selective prescribing of preventive medications
to healthier patients or through health-seeking patients being more
likely to request and fill prescriptions for such medications [7–12].
The healthy adherer effect [6,13,14], also known as “adherence bias”
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Published by Elsevier Inc.[11], or “compliance bias” [1,3], occurs when such patients are more
likely to remain adherent to a preventive therapy. These phenomena
can lead to exaggerated or spurious protective effects of preventive
therapies on adverse outcomes when general health status is not
well measured and is associated with both initiation and/or adher-
ence to the treatment of interest and the study outcome. Unfortu-
nately, general health status and related constructs—frailty, cogni-
tive function, and health-seeking tendencies—are often difficult to
measure in many data sets used in observational research, resulting
in the possibility of residual confounding.
Despite a growing awareness of the healthy user and healthy
adherer effects, few studies to date have attempted to quantify
these effects directly and assess their potential impact on ob-
served rates of clinical events. In a recent study on the healthy
adherer effect, we examined the association between adher-
ence among new users of statins and the use of recommended
preventive tests and services [15]. We found that patients who
were adherent to statins received flu shots, pneumonia vacci-
nations, prostate specific antigen testing, mammograms, and
fecal occult blood tests at significantly higher rates than nonad-
herent patients, suggesting that the former may be more health
seeking. A second study documented an apparent protective
effect of statin adherence on clinical outcomes that should be
Hospital–Division of Pharmacoepidemiology, 1620 Tremont St.,
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
514 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 5 1 3 – 5 2 0biologically unrelated to the clinical need for or use of a statin
[16].
In the present study, we add to our existing work by exploring the
healthy user effect. We hypothesize that initiation of a statin will be
a marker for a healthier lifestyle, so that patients who initiate statins
will have greater rates of preventive service use than age, sex-
matched noninitiators, and lower rates of clinical outcomes that we
expect to be associated with unhealthy lifestyle. Lastly, we assess the
possibility of using receipt of preventive services in the year prior to
statin initiation as a measure of health-seeking tendency. We antic-
ipate that adjustment for receipt of these services will attenuate the
association between statin use and the use of preventive health ser-
vices and occurrence of adverse clinical outcomes during follow-up.
Methods
Data sources and study population
Our study cohort was drawn from a population of patients 65 years
old, who were dually enrolled in Medicare and in the Pennsylvania
Pharmaceutical Assistance Contract for the Elderly (PACE) or the New
Jersey Pharmaceutical Assistance to the Aged and Disabled program
(PAAD). PACE is a state-run pharmaceutical benefit program for
households with incomes less than $17,200 USD, and covers all out-
patient drugs with low patient co-payments of $6 to $9; PAAD pro-
vides similar benefits to New Jersey seniors with incomes up to
$27,676. Our cohort of statin initiators consisted of PACE/Medicare
and PAAD/Medicare enrollees who filled a statin prescription be-
tween 1997 and 2002 without having filled one in the prior 12 months.
We excluded patients who started cerivastatin because the market
withdrawal of cerivastatin in 2001 is likely to have influenced their
statin adherence [17]. We limited our study to a primary prevention
population by excluding all patients who had evidence of myocardial
infarction, ischemic heart disease, coronary artery by-pass graft sur-
gery, or angioplasty. We also excluded patients with diabetes and
peripheral vascular disease, considered coronary artery disease
equivalents. The primary prevention restriction was imposed in or-
der to make the population more homogenous in its clinical need for
Fig. 1 – Schematic of study design for ha statin. For each statin initiator, a noninitiator matched on age, sexand state was selected from the pool of subjects who met study eli-
gibility requirements and were not using a statin on that initiator’s
start date.
Healthy adherer analysis
For our analysis of the association between statin adherence and the
study outcomes, we further restricted the population to statin initi-
ators who survived a 1-year adherence ascertainment period follow-
ing their initiation date, and began follow-up at the end of this 1-year
period. A 1-year adherence ascertainment period was selected in or-
der to capture variability in adherence that might not be observed
during a shorter period.
A schematic of the designs for the healthy user and healthy
adherer analyses is given in Figure 1.
Exposure assessment
Healthy user analysis
In our analysis of the association between statin initiation and the
study outcomes, we carried forward initial exposure status (initiator
vs. noninitiator), with follow-up beginning on the initiation date for
statin users and matched index date for nonusers.
Healthy adherer analysis
For our analysis of the association between adherence and the
study outcomes, adherence was defined as refilling a statin pre-
scription at least once during the adherence ascertainment pe-
riod beginning on the index date for each subject and ending 1
year later (Fig. 1). Almost all prescriptions filled through the
PACE and PAAD program are for a 30-day supply, so fully adher-
ent subjects would be expected to fill 12 prescriptions. Subjects
without a full 1-year adherence ascertainment period due to
early death, loss of PACE or PAAD eligibility, or nursing home
admission were omitted from the analysis. The adherence as-
certainment period was shortened to 90 days in a sensitivity
analysis. In a secondary analysis, we quantified adherence us-
y user and healthy adherer analyses.ealthing the continuous measure proportion of days covered (PDC).
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of full adherence versus complete nonadherence.
Covariates
We obtained baseline demographics, health services use, and
health status information from Medicare and PACE/PAAD enroll-
ment files and health care utilization during the year prior to the
initiation of the statin prescription or to the index date for
matched noninitiators. Covariates included age, sex, race, number
of days spent in hospital, number of physician visits, and presence
of specific diagnoses ascertained from inpatient and outpatient
diagnosis codes.
Study outcomes
Outcomes studied were time to the occurrence of clinical out-
comes and time to receipt of recommended preventive medical
tests and services covered by Medicare. Outcomes were as-
sessed in the year following the index date for matched initia-
tors and noninitiators, and in the year following the adherence
ascertainment period for the analyses of adherent versus non-
adherent subjects. In consultation with clinicians, we selected
clinical outcomes a priori to include those which are not known
to be affected by the use of or clinical need for a statin, but
which may be associated with an unhealthy lifestyle. These
included outcomes sometimes associated with poor adherence
to dietary recommendations (gout, diverticulitis, and gall
stones), dehydration (kidney stones), alcohol consumption and
smoking (peptic ulcers and gastrointestinal bleeds), poor per-
sonal hygiene (skin infections and dental problems such as gin-
givitis, periodontal diseases and diseases of the dental pulp),
poor management of existing medical conditions (inpatient ad-
missions for asthma or chronic obstructive pulmonary disease
[COPD] among subjects with a previous asthma/COPD diagno-
sis), sun exposure (malignant melanoma), and careless or risky
behavior (sexually transmitted diseases, fractures, open
wounds, burns, poisoning, motor vehicle accidents, and falls).
Outcomes defined by tests and preventive services received
were also pre-specified and included bone mineral density
(BMD) testing and screening mammography for women, pros-
tate specific antigen (PSA) testing for men, and fecal occult
blood tests, influenza vaccinations, and pneumococcal vaccina-
tions for both sexes. PSA testing, fecal occult blood tests, influ-
enza vaccinations, and pneumococcal vaccinations are pro-
vided at no cost to Medicare beneficiaries with traditional Part B
coverage, while beneficiaries pay a 20% copayment for screen-
ing mammograms and BMD tests. Lastly, we studied myocardial
infarction (MI) as an outcome likely to be related to statin use,
and nursing home admission and death as outcomes related to
frailty. Time to the first occurrence of each outcome was deter-
mined, with subjects censored by death, nursing home admis-
sion, loss of PACE or PAAD eligibility, or by the administrative
end of follow-up (365 days after the start of follow-up).
We have previously reported results from an analysis of the
association between adherence and preventive service use in
PACE/Medicare enrollees [15]. Because our new analyses were con-
ucted in a larger population including PAAD/Medicare enrollees,
e repeated the original analyses on this population using the
ame adherence definition and methodology to provide compara-
le estimates.
Statistical analysis
The relationships between each outcome and statin initiation
and adherence were examined using both an unadjusted and a
multivariable adjusted Cox proportional hazards model. The
first Cox model was stratified on 5-year age category, sex, and
state. The second model was stratified on age, sex, and state andincluded the following covariates: Charlson comorbidity score
[18], number of medications used, physician visits, days in hos-
pital, days in nursing home during the baseline period, history
during the baseline period of chronic obstructive pulmonary
disease, obesity, stroke or transient ischemic attack, hyperten-
sion, congestive heart failure, atrial fibrillation, dementia, de-
pression, liver disease, rheumatoid arthritis, osteoarthritis, hip
fracture, and cancer. In a third analysis, we attempted to adjust
for health-seeking tendency to see whether this attenuated our
effect estimates. We treated preventive service use in the year
prior to the index date as a proxy for health seeking, including
indicators for use of each of the six preventive services in the
model. Due to the anticipated small number of clinical out-
comes and in the interest of obtaining a summary measure, we
conducted an additional composite analysis in which we ana-
lyzed the total number of different clinical and service use event
types for each patient during follow-up, using a Poisson regres-
sion model with follow-up time as an offset and controlling for
the same covariates listed above. We estimated the over disper-
sion parameter using the Pearson method. In a secondary anal-
ysis, we used propensity score methods to adjust for differences
between statin initiators and noninitiators and adherent and
nonadherent subjects. These analyses are described in detail in
the appendix. Data analyses were performed in SAS V9.0 (SAS
Institute Inc., Cary, NC).
This study was approved by the Partners Healthcare Institu-
tional Review Board and is covered under Data Use Agreements in
place with the Centers for Medicare & Medicaid Services, PACE,
and PAAD. All personal identifiers were removed from the analytic
datasets.
Results
Study population
Healthy user analysis sample
A total of 98,400 patients initiated a statin and met system use
criteria between 1996 and 2002. Excluding 54,819 patients with
evidence of existing coronary artery disease, diabetes, or periph-
eral vascular disease and 138 lacking continuous Medicare Part B
enrollment left a population of 43,443 patients, 38,585 of whom
were matched by age, sex, and state to eligible nonusers. This
population of statin initiators, described in column 1 of Table 1,
as predominantly female (84%), had a mean age of 76, and had
n average of nine physician visits during the 1-year baseline
eriod. Osteoarthritis (18.3%), COPD (19.6%), and atrial fibrilla-
ion (8.1%) were common comorbid conditions. The matched
tatin noninitiators were more likely to have been hospitalized
r in a nursing home in past year, were more likely to have
sthma/COPD, a prior hip fracture, cancer, or rheumatoid ar-
hritis, but were less likely to be obese. Noninitiators also had
ower rates of all preventive services and physician visits, and
ook fewer different medications.
Healthy adherer analysis sample
For our analysis of the association between statin adherence and
the study outcomes, we restricted our population of statin initia-
tors to the 29,675 subjects who survived the 1-year adherence as-
certainment period without leaving the PACE/PAAD program or
entering a nursing home so that 1-year adherence patterns could
be assessed. When adherence was defined as filling two or more
statin prescriptions in the year following initiation, 88% of statin
initiators were classified as adherent. The mean number of days
covered during the year following initiation was 234 (standard de-
viation: 120; range: 7 to 365), yielding a mean proportion of days
516 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 5 1 3 – 5 2 0covered (PDC) of 64%. Compared to the 3,510 subjects who filled
only one prescription, adherent subjects were less likely to have
been hospitalized in the past year, had lower rates of COPD, had
fewer physician visits and different medications in the prior year,
and were more likely to have received all preventive services ex-
cept for BMD testing in the prior year.
Preventive service use outcomes
Healthy user analysis
Of the 38,585 statin initiators, 39.1% received a flu shot, 9.4%
received a fecal occult blood test, and 5.9% received a pneumo-
nia vaccination in the 1-year follow-up period (Table 2). Among
women, 19.2% received a mammogram, and 7.2% received a
bone mineral density test. Among men, 23.6% received a PSA
test. In an analysis adjusted for clinical and demographic cova-
riates (model 2), statin initiators as compared to matched
noninitiators had significantly higher rates of use for all of the
Table 1 – Characteristics of study subjects.
Characteristic assessed during
1-year baseline period
Statin initiators a
noninitiators inclu
user ana
Statin
initiators
Noninit
matched
sex, st
N 38,585 38,585
Pennsylvania residents 46.61 46
Age (mean) 76.05 76
Female 84.23 84
Race
Black 8.56 8
White 88.18 89
Other 3.26 2
Number of physician visits (mean) 8.55 8
Number of medications used (mean) 7.12 7
Charlson comorbidity score (mean) 1.12 1
Acute care hospitalization 11.80 13
Nursing home stay 1.35 2
History of chronic obstructive
pulmonary disease
19.63 21
History of stroke 2.65 1
History of dementia 3.50 4
History of depression 7.97 8
History of congestive heart failure 5.91 5
History of hip fracture 0.85 1
History of obesity 3.07 2
History of cancer 1.13 2
History of liver disease 0.11 0
History of osteoarthritis 18.36 17
History of rheumatoid arthritis 1.73 2
History of atrial fibrillation 8.15 8
History of hypertension 69.63 58
Preventive service use
Bone mineral density test* 6.45 5
Fecal occult blood test 12.95 10
Influenza vaccination 44.09 40
Mammography* 19.30 16
Prostate specific antigen test* 6.62 5
Pneumonia vaccination 7.31 6
* Bone mineral density testing percent is among women65 years ol
percent is among men.tests studied excluding PSA testing which was borderline sig-nificant, resulting in a 9% higher overall rate of receiving pre-
ventive services (95% confidence interval [CI]: 7%–11%) among
women and a 10% higher rate of preventive service use among
men (95% CI: 6%–15%). Further adjustment for indicators of past
preventive service use (model 3) reduced the overall preventive
service use rate ratios to 1.05 (1.03–1.07) for women and 1.04
(0.99 –1.08) for men.
Healthy adherer analysis
Consistent with our previously reported results [15], the 26,165
adherent subjects had higher rates of all tests than did the 3510
nonadherent subjects adjusting for clinical and demographic co-
variates (model 2, Table 3), yielding pooled rate ratios for preven-
tive service use of 1.23 (95% CI: 1.17–1.28) among women and 1.15
(1.04–1.27) among men. Further adjustment for indicators of past
preventive service use (model 3) attenuated these estimates to
1.14 (95% CI: 1.10–1.20) and 1.11 (1.01–1.23). Modeling the effect of
adherence using PDC as a continuous outcome yielded more ex-
atched
n healthy
Statin initiators surviving 1 year from
initiation date included in healthy
adherer analysis
s
e,
P value Statin
initiators—
adherent
Statin
initiators—
nonadherent
P value
Frequency (%)/mean
26,165 3,510
1 48.05 39.37 0.0001
0.862 75.74 76.24 0.0001
1 84.88 85.36 0.46
0.0001 0.0001
8.15 10.11
88.74 85.13
3.11 4.76
0.0001 8.35 8.84 0.0001
0.0001 7.14 7.38 0.0001
0.1505 1.06 1.09 0.2036
0.0001 10.51 11.34 0.1362
0.0001 0.91 0.91 0.9724
0.0001 18.73 20.74 0.0043
0.0001 2.20 1.79 0.1192
0.0001 2.68 2.45 0.4205
0.0038 7.21 7.44 0.6306
0.2126 5.50 4.62 0.0294
0.0001 0.83 0.68 0.3786
0.0005 3.06 3.62 0.0751
0.0001 0.93 1.34 0.0203
0.0046 0.10 0.20 0.0783
0.0052 18.28 18.80 0.4486
0.0001 1.59 1.88 0.1949
0.1785 7.43 6.78 0.1665
0.0001 70.34 64.33 0.0001
0.0001 5.73 5.56 0.67
0.0001 13.87 12.56 0.0353
0.0001 44.29 36.75 0.0001
0.0001 18.98 15.30 0.0001
0.0001 6.33 6.84 0.24
0.0001 7.40 6.61 0.093
mmography percent is among women, and prostate specific antigennd m
ded i
lysis
iator
on ag
ate
.61
.06
.23
.05
.35
.60
.04
.30
.14
.53
.04
.35
.22
.80
.54
.70
.37
.65
.35
.18
.58
.52
.42
.38
.61
.77
.56
.07
.01
.14
d, matreme estimates representing the effect of full adherence com-
is wa
517V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 5 1 3 – 5 2 0pared to complete nonadherence. The rate ratios for the compos-
ite preventive service use outcomes estimated from model 2 were
1.36 (95% CI: 1.30–1.42) among women and 1.25 (1.14–1.38) among
men (Appendix table 1 at: doi:10.1016/j.jval.2010.10.033). These
decreased to 1.22 (95% CI: 1.17–1.27) and 1.18 (1.07–1.29) after
further adjustment for past preventive service use (model 3).
Results from a sensitivity analysis in which the adherence ascertain-
ment period was shortened to 90 days were attenuated slightly com-
pared to those obtained using a 365-day adherence ascertainment
period. (hazard ratio [HR]  1.19 versus 1.23 among women, HR 
1.11 versus 1.15 among men, see appendix at: doi:10.1016/j.jval
Table 2 – Analysis of healthy user effect: event counts, rate
noninitiators.
Statin initiat
(N  38,585
N events
Myocardial infarction 370
Death 601
Nursing home admission 1236
Preventive service use outcomes
Composite–males 5072
Composite–females 26,582
Bone mineral density test‡ 2351
Prostate specific antigen test§ 1437
Fecal occult blood test‡ 3639
Mammography‡ 6245
Influenza vaccination 15,099
Pneumonia vaccination 2265
Clinical outcomes not known to be related
to statin use
Composite 15,772
Asthma/COPD hospitalization among
subjects with asthma/COPD
736
Burns 139
Dental problems 92
Diverticulitis 2793
Falls 1227
Food-borne bacterial illness 359
Fractures 1774
Gall stones 693
Gout 848
Kidney stones 424
Malignant melanoma 110
Migraine 311
Motor vehicle accident 103
Open wound 977
Peptic ulcer/gastrointestinal bleed 2061
Poisoning 272
Sexually transmitted disease 103
Skin infections 2358
CI, confidence interval; COPD, chronic obstructive pulmonary diseas
* Rate is per 100 person-years.
† Rate ratios for individual outcomes were estimated from a Cox pro
and adjusted for race, Charlson comorbidity score, number of medi
during the baseline period, and history during the baseline perio
ischemic attack, hypertension, congestive heart failure, atrial fibril
thritis, hip fracture, and cancer (model 2). Rate ratios for composite o
covariates.
‡ Prostate specific antigen test, fecal occult blood test, and mammog
detected by the screening test. Bone mineral density testing analys.2010.10.033).Clinical outcomes
Healthy user analysis
In the follow-up period, of the clinical outcomes studied, divertic-
ulitis (7.2%), skin infections (6.1%), fractures (4.6%), and peptic ul-
cers and gastrointestinal bleeds (5.3%) were the most common
clinical outcomes among statin initiators, as shown in Table 2.
Compared to noninitiators, statin initiators had significantly
lower rates of falls, fractures, open wounds, skin infections,
peptic ulcer disease/gastrointestinal bleeds, and asthma/COPD
hospitalizations among patients with a prior diagnosis of
d rate ratios in statin initiators vs. matched
Noninitiators matched
on age, sex, and state
(N  38,585)
Rate ratio, statin
initiators vs.
matched
noninitiators
(95% CI)†e
† N events Rate*
9 355 1.08 0.98 (0.84, 1.13)
7 1110 3.36 0.58 (0.52, 0.64)
3 1794 5.43 0.69 (0.64, 0.75)
9 4,300 85.52 1.10 (1.06, 1.14)
4 23,402 83.55 1.09 (1.07, 1.11)
9 1236 3.63 1.17 (1.11, 1.25)
2 1228 32.42 1.08 (1, 1.16)
9 3291 10.72 1.06 (1.01, 1.11)
8 5199 21.75 1.15 (1.11, 1.19)
8 13,444 50.82 1.09 (1.06, 1.12)
9 1915 5.96 1.15 (1.08, 1.23)
7 17,462 52.85 0.87 (0.85, 0.89)
1141 19.96 0.70 (0.64, 0.77)
1 117 0.35 1.16 (0.90, 1.49)
7 107 0.32 0.86 (0.65, 1.14)
6 2757 8.71 0.99 (0.94, 1.05)
6 1567 4.83 0.78 (0.72, 0.84)
6 389 1.18 0.90 (0.78, 1.05)
4 2216 6.91 0.81 (0.76, 0.86)
6 697 2.13 0.97 (0.87, 1.08)
3 732 2.24 1.03 (0.94, 1.14)
5 409 1.25 0.99 (0.86, 1.14)
2 113 0.34 0.99 (0.76, 1.3)
2 302 0.92 1.00 (0.85, 1.17)
73 0.22 1.41 (1.04, 1.91)
1 1186 3.65 0.81 (0.74, 0.88)
4 2201 6.87 0.91 (0.86, 0.97)
281 0.85 0.97 (0.82, 1.15)
85 0.26 1.15 (0.86, 1.54)
9 2558 8.05 0.89 (0.85, 0.95)
nal hazards regression stratified on age, sex, and state of residence,
ns used, physician visits, days in hospital, and days in nursing home
hronic obstructive pulmonary disease, obesity, stroke or transient
, dementia, depression, liver disease, rheumatoid arthritis, osteoar-
mes were estimated using a Poisson regression adjusted for the same
analyses were restricted to subjects without a history of the cancer
s restricted to women without a history of hip fracture.s, an
ors
)
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518 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 5 1 3 – 5 2 0statin initiators relative to noninitiators estimated from model
2 was 0.89 (95% CI: 0.86 – 0.91). Compared to noninitiators, statin
initiators appeared to be protected against both death (HR: 0.58,
95% CI: 0.52– 0.64) and nursing home admission (HR: 0.69, 95%
CI: 0.64 – 0.75). The rate of MI was not significantly different be-
tween these groups.
Healthy adherer analysis
As shown in Table 3, among statin initiators, adherent patients
had significantly lower rates of food-borne bacterial illness and
gall stones. Adherent patients had adverse clinical outcomes at
a rate of 0.93 (95% CI: 0.87– 0.99) times that of nonadherent sub-
jects as estimated from model 2. Modeling adherence as contin-
Table 3 – Analysis of healthy adherer effect: event counts,
initiators.
Adheren
(N 
N events
Myocardial Infarction 221
Death 442
Nursing home admission 871
Preventive service use outcomes
Composite–males 3269
Composite–females 19,216
Bone mineral density test‡ 1646
Prostate specific antigen test‡ 962
Fecal occult blood test‡ 2521
Mammography‡ 4415
Influenza vaccination 10,339
Pneumonia vaccination 1566
Clinical outcomes not known to be related to statin use
Composite 11,139
Asthma/COPD hospitalization among subjects
with asthma/COPD
496
Burns 95
Dental problems 48
Diverticulitis 1974
Falls 944
Food-borne bacterial illness 266
Fractures 1242
Gall stones 466
Gout 603
Kidney stones 299
Malignant melanoma 66
Migraine 192
Motor vehicle accident 58
Open wound 695
Peptic ulcer/gastrointestinal bleed 1423
Poisoning 186
Sexually transmitted disease 65
Skin infections 1689
CI, confidence interval; COPD, chronic obstructive pulmonary diseas
* Rate is per 100 person-years
† Rate ratios for individual outcomes were estimated from a Cox propo
adjusted for race, Charlson comorbidity score, number of medications
baseline period, and history during the baseline period of chronic o
hypertension, congestive heart failure, atrial fibrillation, dementia, de
cancer (model 2). Rate ratios for composite outcomes were estimated
‡ Prostate specific antigen test, fecal occult blood test, and mammog
detected by the screening test. Bone mineral density testing analysuous PDC yielded a rate ratio of 0.89 (95% CI: 0.83– 0.95) for the Rcomposite clinical end point (see Appendix table 1 at: doi:
10.1016/j.jval.2010.10.033). Adjustment for past use of preven-
tive services (model 3) did not attenuate either estimate. Short-
ening the adherence ascertainment period from 365 days to 90
days yielded results similar to those from the primary analysis
(HR  0.94, 0.89 – 0.98, see appendix at: doi:10.1016/j.jval
2010.10.033). The rate of MI in adherent subjects was 0.74 times
hat in nonadherent subjects (95% CI: 0.52–1.04). While adher-
nce was associated with lower mortality rates (HR: 0.72, 95% CI:
.57– 0.91), it had no apparent effect on nursing home admission
HR: 0.98, 0.81–1.19).
There were no meaningful differences between the results ob-
ained within the individual states, New Jersey and Pennsylvania.
, and rate ratios in adherent vs. nonadherent statin
bjects
65)
Nonadherent
subjects
(N  3,510)
Rate ratio,
adherent vs.
nonadherent
patients
(95% CI)†Rate* N events Rate*
0.96 39 1.27 0.74 (0.52, 1.04)
1.91 81 2.63 0.72 (0.57, 0.91)
3.76 122 3.96 0.98 (0.81, 1.19)
96.04 371 84.66 1.15 (1.04, 1.27)
97.24 2092 79.28 1.23 (1.17, 1.28)
8.75 177 6.96 1.35 (1.16, 1.58)
37.54 115 35.2 1.13 (0.93, 1.37)
11.7 283 9.81 1.18 (1.04, 1.33)
26.26 459 19.94 1.30 (1.18, 1.44)
57.29 1153 45.77 1.27 (1.19, 1.35)
6.98 162 5.41 1.28 (1.09, 1.51)
48.08 1644 53.43 0.93 (0.87, 0.99)
13.91 87 16.78 0.83 (0.66, 1.04)
0.41 13 0.42 1.04 (0.58, 1.87)
0.21 7 0.23 1.00 (0.45, 2.21)
8.91 291 9.95 0.95 (0.84, 1.08)
4.14 129 4.27 0.97 (0.81, 1.17)
1.15 53 1.74 0.69 (0.51, 0.92)
5.49 182 6.09 0.93 (0.79, 1.09)
2.03 81 2.66 0.78 (0.62, 0.99)
2.64 67 2.21 1.16 (0.90, 1.49)
1.3 47 1.54 0.86 (0.63, 1.17)
0.29 4 0.13 2.22 (0.81, 6.11)
0.83 32 1.05 0.85 (0.59, 1.25)
0.25 8 0.26 1.06 (0.50, 2.22)
3.04 96 3.16 0.97 (0.78, 1.2)
6.33 221 7.44 0.88 (0.77, 1.02)
0.81 25 0.82 1.00 (0.66, 1.52)
0.28 14 0.46 0.73 (0.41, 1.31)
7.58 229 7.73 1.03 (0.89, 1.18)
al hazards regression stratified on age, sex, and state of residence, and
, physician visits, days in hospital, and days in nursing home during the
ctive pulmonary disease, obesity, stroke or transient ischemic attack,
ion, liver disease, rheumatoid arthritis, osteoarthritis, hip fracture, and
a Poisson regression adjusted for the same covariates.
analyses were restricted to subjects without a history of the cancer
s restricted to women without a history of hip fracture.rates
t su
26,1
e.
rtion
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bstru
press
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raphyesults adjusted for propensity score decile (appendix tables 2 and 3
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presented in Tables 2 and 3.
Discussion
In patients without evidence of coronary artery disease, diabe-
tes, or peripheral vascular disease, statin initiation and statin
adherence were both associated with increased use of preven-
tive services and an apparent protective effect against a range of
clinical outcomes not known to be related to the need for or use
of a statin, but possibly associated with an unhealthy lifestyle.
Because statin initiation and adherence do not directly cause
preventive service use or protect subjects against the clinical
outcomes evaluated, the observed associations must be attrib-
utable to other factors. We think it likely that initiating and
adhering to preventive treatment for an asymptomatic condi-
tion are markers of health-seeking tendencies and better gen-
eral health status, such that these patients are more likely to
engage in preventive service use and less likely to suffer out-
comes potentially associated with an unhealthy lifestyle.
Adherent versus nonadherent subjects differed more in their
preventive service use than did statin initiators versus noninitia-
tors. One possible reason for this is that while patients play a role
in statin initiation by deciding to fill an initial prescription, statin
initiation is driven in large part by a physician’s decision to pre-
scribe a statin based on cholesterol levels and cardiovascular risk
factors. For this reason, statin initiation is a much weaker indica-
tor of health-seeking behavior than is the subsequent decision to
adhere to a statin. While statin initiators are likely to have greater
cardiovascular disease risk, the higher rates of prior hip fracture,
hospitalization, and nursing home admission among noninitia-
tors suggest that noninitiators may be a physically frailer popula-
tion, less likely to be prescribed a preventive therapy. Our obser-
vation that statin initiation was associated with a 42% reduction in
the risk of mortality and a 31% reduction in the risk of nursing
home admission is also consistent with this hypothesis. These
findings are also consistent with past work which found a negative
association between statin initiation and frailty markers, and a
strong apparent protective effect of statin initiation on mortality
[7,8].
Adjusting for prior use of preventive tests and services at-
tenuated the association between statin use and the use of
these services during follow-up, suggesting that past preventive
services use may be a marker for health-seeking behavior. Thus,
adjusting for past use of preventive services may be one way of
reducing the association between preventive drug use and
health-seeking behavior. However, even after adjustment for
past service use, statin users still had higher rates of preventive
service use during follow-up. Furthermore, adjusting for past
service use did not attenuate the protective effects of statins on
the clinical outcomes we studied. One possible explanation,
supported by the residual association between statin use and
preventive service use, is that prior use of BMD tests, flu shots,
mammograms, PSA testing, and fecal occult blood tests are an
incomplete measure of a patient’s overall health-seeking ten-
dency. Furthermore, the tendency to seek formal medical care
may be only one component of a healthy lifestyle, which in turn,
may be only one possible contributor to a patient’s general
health status.
The association between statin initiation and adherence and
the majority of the clinical outcomes we studied tended toward
a protective effect. However, this was not the case for malignant
melanoma which occurred with a higher frequency in subjects
who initiated and remained adherent to a statin. Malignant
melanoma is likely subject to screening bias, such that patientswho are more engaged in their own health are more likely to
have cancerous lesions detected.
These results support the notion of healthy user and healthy
adherer effects, but several alternative explanations should be
considered. While our outcomes were selected by consensus
among two clinicians, it is possible that future research will show
that one or more of these outcomes is biologically affected by ei-
ther statin use or by conditions such as cardiovascular disease or
hypercholesterolemia related to the clinical need for a statin. For
example, despite results of secondary analyses of RCT data [19],
some clinicians believe statins do have a protective effect on hip
fracture.
Our study suffers from several limitations. We defined ad-
herence as refilling an initial statin prescription in order to be
consistent with the definition used in our previous study [15],
because refilling versus not refilling provides an extreme con-
trast, and because the effect of refilling versus not refilling is
easily interpreted. While refilling is correlated with both the
medication possession ratio (MPR), which is the adherence
measure recommended by the International Society of Pharma-
ceutical Outcomes Research (ISPOR) Medication and Compli-
ance Special Interest Group and with persistence, refilling is not
a pure measure of either adherence, which has been defined by
the ISPOR SIG as “the extent to which a patient acts in accor-
dance with the prescribed interval, and dose of a dosing regi-
men” or persistence, which has been defined as “the duration of
time from initiation to discontinuation of therapy” [20]. Our
study is also limited in generalizability. We studied a predomi-
nantly female, frail, elderly population from two states and a
single income bracket. Variability in health-seeking behavior
and health status may be substantially different in younger,
healthier, more affluent populations; a recent study among
statin initiators in British Columbia found stronger apparent
protective effects of adherence on outcomes such as accidents
than those reported here [16]. In addition, the relationship be-
tween initiation, adherence, and health-seeking tendencies
may vary by drug class and outcome; this association is likely
stronger for medications used to treat asymptomatic conditions
than symptomatic ones, and for outcomes with a potential be-
havioral component than those without.
It is possible that our sample selection process could have
contributed to the observed associations between statin adher-
ence and the outcomes of interest. In order for statin initiators
to be selected into the primary analysis sample, they must have
survived without a nursing home admission during the 1-year
adherence ascertainment period. If meeting these selection cri-
teria depends on variables such as health status, that are asso-
ciated with increased use of preventive services and decreased
risk of adverse clinical outcomes, and if adherence to statins
also contributes to selection (e.g., by preventing mortality dur-
ing the ascertainment period), then the study design itself may
cause a spurious association known as “collider bias” between
adherence and health status [21–23]. We tested the contribution
of selection bias to our findings by shortening the adherence
ascertainment period to 90 days in a sensitivity analysis. The
results from this analysis were very similar to those from the
primary analysis. Assuming that filling a statin two or more
times versus only once is unlikely to affect 90-day survival, the
results of our sensitivity analysis can be taken as evidence that
our results were not completely attributable to conditioning on
a collider.
Further research is needed to investigate other potential
causes of the observed effects and ways of guarding against
them in observational studies. Assuming adequate measures of
health-seeking tendency and health status can be developed,
statistical adjustment for such measures can reduce or ideally
eliminate the healthy user and healthy adherer effects. For ex-
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prior to the flu season reported in a recent article was attenu-
ated when the analysis was adjusted for measures of functional
status [24]. Study design can also reduce the potential for
healthy user and healthy adherer effects. Adherence bias can be
reduced through the use of a new user design where exposure is
assumed to continue through follow-up in an “intention-to-
treat” approach as has been used in many recent studies of
medications [25–29]. This design reduces the degree to which
the treated group becomes enriched with adherent patients
who may be healthier and more health seeking than patients in
the comparator group. Healthy user bias can be minimized
through the use of an active comparator group of subjects ini-
tiating a different therapy. Through this design, the exposed
and comparator groups become similar in having initiated a
drug and therefore in the behavioral and health status charac-
teristics that may be associated with initiating a preventive
therapy. While the choice of an appropriate comparator can be
challenging, this design has been used recently in several stud-
ies [30,31]. One possible tool for detecting the presence of
healthy user and healthy adherer bias is the use of control out-
comes. For example, differences in rates of preventive service
use or outcomes that should not be associated with exposure
but might be influenced by health-seeking tendency can be as-
sessed between treatment and comparator groups.
These findings suggest that differences in health-seeking be-
havior, as measured by differences in preventive service use, exist
between initiators and noninitiators of statin treatment, as well as
between adherent and nonadherent patients. The presence of
these differences raises the possibility of healthy user and healthy
adherer biases in studies of the association between initiation or
adherence and adverse clinical outcomes. In fact, we find that
both statin initiation and adherence are associated with reduced
rates of clinical outcomes unlikely to be biologically related to ei-
ther the need for or use of a statin. These findings—and the use of
methods to diagnose and reduce the risk of confounding by
healthy user and healthy adherer effects—should be considered
by researchers conducting non-randomized studies of preventive
therapies and by clinicians and policy-makers evaluating the find-
ings from such studies.
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